CL2020001183A1 - Implantes de liberación sostenida para reducir la presión intraocular con duración prolongada del efecto. - Google Patents

Implantes de liberación sostenida para reducir la presión intraocular con duración prolongada del efecto.

Info

Publication number
CL2020001183A1
CL2020001183A1 CL2020001183A CL2020001183A CL2020001183A1 CL 2020001183 A1 CL2020001183 A1 CL 2020001183A1 CL 2020001183 A CL2020001183 A CL 2020001183A CL 2020001183 A CL2020001183 A CL 2020001183A CL 2020001183 A1 CL2020001183 A1 CL 2020001183A1
Authority
CL
Chile
Prior art keywords
intraocular pressure
sustained
effect
prolonged duration
reduce intraocular
Prior art date
Application number
CL2020001183A
Other languages
English (en)
Inventor
Michael R Robinson
Marina Bejanian
Michelle Y Chen
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of CL2020001183A1 publication Critical patent/CL2020001183A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
    • A61F9/0017—Introducing ophthalmic products into the ocular cavity or retaining products therein implantable in, or in contact with, the eye, e.g. ocular inserts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/007—Methods or devices for eye surgery
    • A61F9/00781—Apparatus for modifying intraocular pressure, e.g. for glaucoma treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Surgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Prostheses (AREA)

Abstract

EN ESTE DOCUMENTO SE DESCRIBEN LOS MÉTODOS PARA EL TRATAMIENTO DEL AUMENTO DE LA PRESIÓN INTRAOCULAR CON IMPLANTES INTRAOCULARES INTRACÁMARA. LA LIBERACIÓN CONTROLADA Y SOSTENIDA DEL BIMATOPROST A LA CÁMARA ANTERIOR DEL OJO PUEDE SER EFECTIVA PARA TRATAR UN OJO POR AL MENOS UN AÑO O MÁS PARA LA REDUCCIÓN DE LA IOP.
CL2020001183A 2017-11-09 2020-05-05 Implantes de liberación sostenida para reducir la presión intraocular con duración prolongada del efecto. CL2020001183A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762583967P 2017-11-09 2017-11-09
US201862683337P 2018-06-11 2018-06-11

Publications (1)

Publication Number Publication Date
CL2020001183A1 true CL2020001183A1 (es) 2020-11-06

Family

ID=64457124

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2020001183A CL2020001183A1 (es) 2017-11-09 2020-05-05 Implantes de liberación sostenida para reducir la presión intraocular con duración prolongada del efecto.

Country Status (16)

Country Link
US (2) US20190192341A1 (es)
EP (1) EP3706717A1 (es)
JP (2) JP2021502366A (es)
KR (1) KR20200086289A (es)
CN (1) CN111315361A (es)
AU (1) AU2018366214A1 (es)
BR (1) BR112020009224A2 (es)
CA (1) CA3080908A1 (es)
CL (1) CL2020001183A1 (es)
CO (1) CO2020006924A2 (es)
IL (1) IL273946A (es)
MX (2) MX2020004730A (es)
PH (1) PH12020550550A1 (es)
RU (1) RU2020113494A (es)
SG (1) SG11202004126XA (es)
WO (1) WO2019094652A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015066548A1 (en) * 2013-10-31 2015-05-07 Allergan, Inc. Prostamide-containing intraocular implants and methods of use thereof
CA3144406A1 (en) 2019-06-27 2020-12-30 Layerbio, Inc. Ocular device delivery methods and systems
MX2022009435A (es) * 2020-02-06 2022-08-25 Ocular Therapeutix Inc Composiciones y metodos para el tratamiento de enfermedades oculares.
EP4178506A1 (en) 2020-07-10 2023-05-17 Allergan, Inc. Posterior chamber delivery device for sustained release implant
WO2022020347A1 (en) * 2020-07-21 2022-01-27 Allergan, Inc. Intraocular implant with high loading of a prostamide

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5688819A (en) 1992-09-21 1997-11-18 Allergan Cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
US5834498A (en) 1992-09-21 1998-11-10 Allergan Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
US7993634B2 (en) * 2004-04-30 2011-08-09 Allergan, Inc. Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods
US7799336B2 (en) 2004-04-30 2010-09-21 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
KR102337046B1 (ko) * 2010-01-22 2021-12-08 알러간, 인코포레이티드 전방내 서방성 치료제 이식물
EP2701682A1 (en) * 2011-04-29 2014-03-05 Allergan, Inc. Solvent cast film sustained release latanoprost implant
WO2015066548A1 (en) * 2013-10-31 2015-05-07 Allergan, Inc. Prostamide-containing intraocular implants and methods of use thereof
EP3076948B1 (en) * 2013-12-06 2020-11-18 Allergan, Inc. Intracameral implant for treatment of an ocular condition
US20210228408A1 (en) * 2015-07-23 2021-07-29 Allergan, Inc. Glaucoma Treatment Via Intracameral Ocular Implants

Also Published As

Publication number Publication date
JP2021502366A (ja) 2021-01-28
EP3706717A1 (en) 2020-09-16
CA3080908A1 (en) 2019-05-16
IL273946A (en) 2020-05-31
BR112020009224A2 (pt) 2020-10-13
PH12020550550A1 (en) 2021-03-22
CN111315361A (zh) 2020-06-19
KR20200086289A (ko) 2020-07-16
US20190192341A1 (en) 2019-06-27
RU2020113494A3 (es) 2021-12-09
MX2023011426A (es) 2023-10-17
RU2020113494A (ru) 2021-12-09
CO2020006924A2 (es) 2020-06-19
WO2019094652A1 (en) 2019-05-16
JP2024032731A (ja) 2024-03-12
MX2020004730A (es) 2020-08-13
AU2018366214A1 (en) 2020-05-14
US20240130890A1 (en) 2024-04-25
SG11202004126XA (en) 2020-06-29

Similar Documents

Publication Publication Date Title
CL2020001183A1 (es) Implantes de liberación sostenida para reducir la presión intraocular con duración prolongada del efecto.
PH12018500658A1 (en) Methods of treating intraocular pressure with activators of tie-2
CL2021001228A1 (es) Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad de nlrp
PT3681500T (pt) Utilização do cloridrato de pilocarpina para o tratamento da presbiopia
IL281773A (en) Eye preparation for the treatment of dry eye disease
CL2019003789A1 (es) Tratamiento con plasminógeno de afecciones asociadas a la sobreexpresión de pai-1.
MX2022010333A (es) Implante ocular que contiene un inhibidor de la tirosina cinasa.
IL277557A (en) Self-assembling peptidomimetics and peptidomimetics for the treatment of eye diseases
NZ746468A (en) Methods of treating ocular conditions
PH12021550621A1 (en) Ophthalmic compositions for treatment of ocular surface damage and symptoms of dryness
MY177504A (en) Ophthalmic composition for the treatment of ocular infection
CL2021000580A1 (es) Uso de inhibidores de la caseina quinasa 1 para el tratamiento de enfermedades vasculares.
MX2017007578A (es) Farmacoterapia para prevenir o tratar glaucoma.
RU2014140798A (ru) Способ коррекции фиброзно-измененных фильтрационных подушек, возникающих в послеоперационном периоде при хирургии глаукомы
MX2019011925A (es) Conjugados y derivados de prostaglandina para tratar el glaucoma y la hipertension ocular.
MX2021013048A (es) Insertos de hidrogel intracanalicular para el suministro de anestesicos.
AR107460A1 (es) Gabapentina oftálmica para el tratamiento de las úlceras corneales
CL2021002152A1 (es) Métodos para tratar el dolor de la superficie ocular
IL282898A (en) Ophthalmic compounds and methods for treating skin and eye diseases
UY33562A (es) Agonistas de receptores de bradicinina y su utilización para el tratamiento de la hipertensión ocular y el glaucoma
DK3886858T3 (da) Forbindelser til behandling af øjensygdomme forbundet med for megen vaskularisering
IL280588A (en) Ophthalmic compositions and methods for treating eye problems and skin diseases
GB201914516D0 (en) Treatment of eye disease
ES1240340Y (es) Implante de drenaje en el tratamiento del glaucoma por el procedimiento de esclerectomia profunda no perforante
WO2022104102A3 (en) Materials and methods for treating corneal dysfunction